## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed b	y the R	egistrant 🗵	
Filed b	y a Par	ty other than the Registrant $\ \Box$	
Check	the app	ropriate box:	
	Preliminary Proxy Statement		
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))		
	Definitive Proxy Statement		
$\times$	Definitive Additional Materials		
	Soliciting Material Pursuant to §240.14a-12		
		KALA PHARMACEUTICALS, INC. (Name of Registrant as Specified in Its Charter)	
	(	Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)	
Payme	ment of Filing Fee (Check the appropriate box):		
$\times$	No fee required.		
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.		
	(1)	Title of each class of securities to which transaction applies:	
	(2)	Aggregate number of securities to which transaction applies:	
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	
	(4)	Proposed maximum aggregate value of transaction:	
	(5)	Total fee paid:	
	Fee pa	e paid previously with preliminary materials.	
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.		
	(1)	Amount previously paid:	
	(2)	Form, Schedule or Registration Statement No.:	
	(3)	Filing Party:	
	(4)	Date Filed:	

## KALA PHARMACEUTICALS, INC.

To Be Held On:

June 12, 2018 at 9:00 AM, Eastern Time

at 60 State Street, Boston, Massachusetts 02109

COMPANY NUMBER	
ACCOUNT NUMBER	
CONTROL NUMBER	

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting

If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before 06/01/18.

Please visit http://www.astproxyportal.com/ast/21625/, where the following materials are available for view:

- · Notice of Annual Meeting of Stockholders
- Proxy Statement
- · Form of Electronic Proxy Card
- Annual Report

TO REQUEST MATERIAL:

TELEPHONE: 888-Proxy-NA (888-776-9962) 718-921-8562 (for international callers)

E-MAIL: info@astfinancial.com

WEBSITE: https://us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials

TO VOTE:



ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen

instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the cut-off or meeting date.

IN PERSON: You may vote your shares in person by attending the Annual Meeting.

TELEPHONE: To vote by telephone, please visit www.voteproxy.com to view the materials and to obtain

the toll free number to call.

MAIL: You may request a card by following the instructions above.

NOMINEES:

Mark Iwicki Andrew I, Koven Gregory Perry

Election of Directors: The Board of Directors recommends you vote FOR the following class I directors to serve until 2021:
 To ratify the selection of Deloitte & Touche LLP as Kala Pharmaceuticals, Inc.'s independent registered public accounting firm for the fiscal year ending December 31,

In their discretion, the proxies are authorized to vote upon such other business as may properly come before the Annual Meeting.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE ELECTION OF DIRECTORS AND "FOR" PROPOSAL 2.

Please note that you cannot use this notice to vote by mail.